Table 3. Patients’ Characteristics and On-treatment Response by Sustained Virological Response a,b.
| Characteristics | SVR (-) (n = 16) | SVR (+) (n = 5) | P Value |
|---|---|---|---|
| Gender | > 0.99 c | ||
| Male | 13 (81.3) | 4 (80.0) | |
| Female | 3 (18.8) | 1 (20.0) | |
| Age, y | 29.3 ± 5.4 | 32.2 ± 5.7 | 0.32d |
| BMI, kg/m 2 | 21.0 ± 2.6 | 21.8 ± 5.1 | 0.75d |
| Baseline ALT, IU/L | 51.6 ± 29.0 | 50.0 ± 36.8 | 0.94d |
| Serum ferritin, ng/mL | 850.3 ± 647.1 | 780.2 ± 501.2 | 0.85d |
| rs12979860 | > 0.99c | ||
| CC | 4 (25.0) | 1 (20.0) | |
| Non-CC | 12 (75.0) | 4 (80.0) | |
| Histological findings | > 0.99c | ||
| Fibrosis stage 0-2 | 8 (50.0) | 3 (60.0) | |
| Fibrosis stage 3-4 | 3 (18.8) | 1 (20.0) | |
| Fibrosis stage 5-6 | 5 (31.3) | 1 (20.0) | |
| Serum HCV RNA, IU/mL | 0.64c | ||
| < 800,000 | 8 (50.0) | 3 (60.0) | |
| ≥ 800,000 | 8 (50.0) | 2 (40.0) | |
| EVR | 2 (12.5) | 5 (100) | <0.01c |
| RVR | 1 (6.3) | 3 (60.0) | 0.03c |
a Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; EVR, early virological response; RVR, rapid virological response; SVR, sustained virological response.
b Data are presented as mean ± SD or No. (%).
c Fisher exact test.
d t-test.